Skip to main navigation Skip to search Skip to main content

Regenerative Engineering of Fibrotic Diseases: Mechanistic and Clinical Advances with Bone Marrow Mesenchymal Stem Cells

  • Neeraj Kumar Fuloria
  • , Shivkanya Fuloria
  • , Mahendran Sekar
  • , Omji Porwal
  • , Mohammed Tahir Ansari
  • , Anupam Biswas
  • , Kamal Narain
  • , Sangita Biswas
  • , Sumita Bhatia
  • , Mogana Das Murtey

Research output: Contribution to journal › Review Article › Research › peer-review

Abstract

Bone marrow-derived mesenchymal stem cells (BM-MSCs) have demonstrated significant potential owing to their strong immunomodulatory, anti-inflammatory, and regenerative properties. This review explores the antifibrotic effects of BM-MSCs, focusing on their underlying mechanisms, preclinical evidence, and progress in clinical trials. BM-MSCs moderate fibrosis through immune modulation, regulation of myofibroblast differentiation, and stimulation of matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix (ECM). In pulmonary fibrosis animal models, BM-MSCs reduced TGF-β1 activation and α-SMA and improved lung histology under experimental conditions; some studies included corticosteroid-treated comparators. Additionally, BM-MSCs inhibited the activation of hepatic stellate cells and promoted the polarization of macrophages to an M2 anti-inflammatory phenotype in liver fibrosis. Genetically modified bone marrow-derived mesenchymal stem cells (GM BM-MSCs), such as those transfected with miRNA or overexpressing IL-10, have demonstrated enhanced efficacy in ameliorating myocardial and renal fibrosis through increased homing, paracrine functions, and the inhibition of fibrosis-promoting genes. Early clinical trials of idiopathic pulmonary fibrosis and cirrhotic conditions have indicated their feasibility, safety, and potential efficacy. BM-MSC-derived extracellular vesicles (EVs) provide cell-free therapeutic alternatives with comparable benefits to those of BM-MSCs. Overall, this review provides a comprehensive mechanistic overview of the antifibrotic potential of BM-MSCs, highlighting their translational relevance across organ systems and their promise in regenerative medicine.

Original languageEnglish
Number of pages16
JournalRegenerative Engineering and Translational Medicine
DOIs
Publication statusAccepted/In press - 13 Nov 2025

Keywords

  • BM-MSCs
  • Cardiac fibrosis
  • Fibrosis
  • Kidney fibrosis
  • Liver fibrosis
  • Lung fibrosis

Cite this